Residency · Residency · Cardiothoracic Surgery

Indications for CABG: Guidelines and Evidence

Overview

Coronary artery bypass grafting remains the gold standard for surgical revascularization in specific anatomic and clinical scenarios. Current practice is informed by ACC/AHA guidelines, the SYNTAX scoring system, and a series of landmark randomized trials that define when CABG is superior to percutaneous coronary intervention and when medical therapy alone may suffice.

Current ACC/AHA Guideline Indications for CABG

Class I (Recommended) Indications

CABG is recommended for left main disease with greater than 50% stenosis, particularly when the SYNTAX score exceeds 33 or the anatomy is unfavorable for PCI. Three-vessel disease is another strong indication, especially when accompanied by reduced LVEF, diabetes, or a high SYNTAX score. Two-vessel disease with proximal LAD involvement warrants CABG when associated with extensive ischemia. Patients requiring valve surgery or aortic surgery who have significant concomitant coronary disease should receive CABG at the same operation. CABG is also indicated after failed PCI or when anatomy is unsuitable for PCI, and for acute MI with mechanical complications such as ventricular septal defect or papillary muscle rupture.

Class IIa (Reasonable) Indications

CABG is reasonable for three-vessel disease with intermediate SYNTAX scores (23-32), two-vessel disease without proximal LAD but with a large area of ischemia, and survivors of sudden cardiac death with presumed ischemia-mediated ventricular tachycardia.

Factors Strengthening the Indication for CABG over PCI

Several clinical factors tip the balance toward CABG: diabetes mellitus with multivessel disease, reduced LVEF below 50%, complex coronary anatomy (bifurcation disease, heavy calcification, chronic total occlusions), high SYNTAX score above 33, the need for complete revascularization, and younger age where the long-term survival benefit of arterial grafts is most impactful.

The SYNTAX Score

What It Measures

The SYNTAX score is an angiographic scoring tool that quantifies coronary disease complexity. It accounts for the number of lesions, their location and severity, bifurcation involvement, total occlusion, calcification, thrombus, vessel tortuosity, and diffuse disease. It is scored by the interventionalist and heart team using dedicated software.

SYNTAX Score Categories

SYNTAX Score II

The SYNTAX Score II incorporates clinical variables — age, LVEF, creatinine clearance, COPD, peripheral vascular disease, and female sex — alongside the anatomic SYNTAX score. It provides individualized predicted 4-year mortality for both CABG and PCI and is more discriminating than the anatomic score alone.

Landmark Trials

SYNTAX Trial (2009)

This randomized controlled trial enrolled 1,800 patients with three-vessel and/or left main disease, comparing CABG to PCI with drug-eluting stents. At 5 years, there was no difference in overall mortality, but CABG was superior for repeat revascularization (13.7% vs. 25.9%). In three-vessel disease, CABG was superior for major adverse cardiac and cerebrovascular events (MACCE) across all SYNTAX score tertiles. In left main disease, CABG and PCI were similar at low SYNTAX scores, but CABG was superior at intermediate and high scores. The trial established the SYNTAX score as a decision-making tool and confirmed CABG as the standard for complex coronary disease.

FREEDOM Trial (2012)

This trial randomized 1,900 diabetic patients with multivessel coronary disease to CABG versus PCI with drug-eluting stents. At 5 years, CABG significantly reduced the primary composite endpoint of death, MI, and stroke (18.7% vs. 26.6%, p=0.005). Mortality favored CABG (10.9% vs. 16.3%, p=0.049), and MI was dramatically lower with CABG (6.0% vs. 13.9%, p<0.001). Stroke was higher with CABG (5.2% vs. 2.4%), but this was more than offset by the MI and mortality benefits. FREEDOM established CABG as the standard of care for diabetic patients with multivessel disease regardless of SYNTAX score.

EXCEL Trial (2016/2019)

This trial randomized 1,905 patients with left main disease and low-to-intermediate SYNTAX scores (32 or below) to CABG versus PCI with everolimus-eluting stents. Three-year results showed PCI noninferior to CABG for the primary composite endpoint. However, 5-year results showed a trend toward higher all-cause death with PCI, and repeat revascularization was higher in the PCI group. The trial generated significant controversy because the endpoint definition included periprocedural MI using a biomarker-only definition, which was criticized as favoring PCI. Reanalysis using the universal MI definition showed CABG superiority, and this led to EACTS withdrawing endorsement of the joint guidelines — highlighting how endpoint definitions in surgical trials can materially affect conclusions.

NOBLE Trial (2017)

This trial randomized 1,201 patients with left main disease to CABG versus PCI with biolimus-eluting stents. At 5 years, CABG was superior to PCI for MACCE (19% vs. 29%, p=0.0066), with higher nonprocedural MI and repeat revascularization in the PCI group. The results support CABG for left main disease even at lower SYNTAX scores.

ISCHEMIA Trial (2020)

This large trial randomized 5,179 patients with moderate-to-severe ischemia and stable coronary disease to an invasive strategy (angiography plus revascularization) versus a conservative strategy (optimal medical therapy alone). There was no difference in the primary composite endpoint at 3.2 years. Importantly, left main disease was excluded (detected on pre-randomization CTA). Quality of life improved with the invasive strategy due to less angina. The trial does not negate the benefit of CABG for left main or complex three-vessel disease; rather, it highlights that not all patients with ischemia need revascularization and that medical therapy is a strong baseline treatment.

STICH Trial (2011/2016)

This trial randomized 1,212 patients with ischemic cardiomyopathy (EF 35% or below) and coronary disease amenable to CABG to either CABG plus medical therapy or medical therapy alone. The 10-year follow-up (STICHES) showed that CABG reduced all-cause mortality (58.9% vs. 66.1%, p=0.02) and cardiovascular mortality. This established that CABG improves long-term survival in patients with ischemic cardiomyopathy, even with severely reduced EF.

The Heart Team Approach

Components

The heart team is a multidisciplinary group involving a cardiac surgeon, interventional cardiologist, and often imaging specialists, anesthesiologists, and heart failure specialists. They review coronary anatomy, comorbidities, surgical risk (STS score), SYNTAX score, patient preferences, and frailty. Formal Heart Team discussion is a Class I recommendation in current guidelines for left main and complex multivessel disease.

Factors in the Heart Team Discussion

Key considerations include anatomic complexity (SYNTAX score), clinical factors (diabetes, LVEF, renal function, COPD, age, frailty), the completeness of revascularization achievable by each modality, patient preference and goals of care, and institutional expertise and outcomes.

<image>Decision algorithm flowchart for revascularization strategy: starting with coronary anatomy (left main vs. multivessel vs. single/two-vessel disease), incorporating SYNTAX score categories (low, intermediate, high), clinical modifiers (diabetes, LVEF, age), and leading to recommended strategy (CABG, PCI, or either with Heart Team discussion). Color-coded pathways distinguish clear CABG indications, clear PCI indications, and equipoise zones requiring Heart Team input.</image>

<image>Comparative bar graph illustration showing 5-year outcomes from the SYNTAX, FREEDOM, and NOBLE trials side by side, with CABG versus PCI bars for: all-cause mortality, myocardial infarction, repeat revascularization, and stroke. Each trial is labeled with its patient population (three-vessel/left main, diabetic multivessel, left main respectively). Statistical significance indicators are shown above each comparison.</image>

Clinical Pearls

CABG remains superior to PCI for left main disease with SYNTAX above 33, three-vessel disease (especially with diabetes or reduced EF), and complex coronary anatomy. The FREEDOM trial established CABG as the definitive treatment for diabetic patients with multivessel disease — this is one of the strongest evidence-based indications in cardiac surgery. The EXCEL controversy underscores the importance of endpoint definitions in surgical trials; periprocedural MI defined by biomarkers alone can bias results in favor of PCI. The ISCHEMIA trial does not apply to left main disease patients (who were excluded) and does not diminish CABG indications for appropriate anatomy; it supports medical therapy as a reasonable first-line strategy for stable CAD without left main involvement. STICH/STICHES demonstrated that CABG improves survival in ischemic cardiomyopathy — patients should not be denied surgical revascularization based on low EF alone. The Heart Team approach is a guideline mandate, not a suggestion, and decisions about revascularization strategy for complex CAD should never be made unilaterally. The SYNTAX score is an anatomic tool; the clinical picture (diabetes, LVEF, frailty, patient goals) must be integrated for optimal decision-making.

References

• Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. J Am Coll Cardiol. 2022;79(2):e21-e129.
• Serruys PW, Morice MC, Kappetein AP, et al. SYNTAX trial. N Engl J Med. 2009;360(10):961-972.
• Farkouh ME, Domanski M, Sleeper LA, et al. FREEDOM trial. N Engl J Med. 2012;367(25):2375-2384.
• Stone GW, Kappetein AP, Sabik JF, et al. EXCEL trial 5-year outcomes. N Engl J Med. 2019;381(19):1820-1830.
• Makikallio T, Holm NR, Lindsay M, et al. NOBLE trial. Lancet. 2016;388(10061):2743-2752.
• Maron DJ, Hochman JS, Reynolds HR, et al. ISCHEMIA trial. N Engl J Med. 2020;382(15):1395-1407.
• Velazquez EJ, Lee KL, Jones RH, et al. STICHES trial 10-year follow-up. N Engl J Med. 2016;374(16):1511-1520.

Read this lecture as Markdown